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Aims Cardiac resynchronization therapy (CRT) involves time-consuming procedures to achieve an
optimal programming of the system, at implant as well as during follow-up, when remodelling
occurs. A device equipped with an implantable sensor able to measure peak endocardial acceleration
(PEA) has been recently developed to monitor cardiac function and to guide CRT programming.
During scanning of the atrioventricular delay (AVD), PEA reﬂects both left ventricle (LV) contractility
(LVdP/dtmax) and transmitral ﬂow. A new CRT optimization algorithm, based on recording of PEA
(PEAarea method) was developed, and compared with measurements of LVdP/dtmax, to identify an
optimal CRT conﬁguration.
Methods and results We studied 15 patients in New York Heart Association classes II–IV and with a QRS
duration .130 ms, who had undergone implantation of a biventricular (BiV) pulse generator connected
to a right ventricular (RV) PEA sensor. At a mean of 39+15 days after implantation of the CRTsystem,
the patients underwent cardiac catheterization. During single-chamber LV or during BiV stimulation,
with initial RV or LV stimulation, and at settings of interventricular intervals between 0 and 40 ms,
the AVD was scanned between 60 and 220 ms, while LV dP/dtmax and PEA were measured. The area of
PEA curve (PEAarea method) was estimated as the average of PEA values measured during AVD scanning.
A  10% increase in LVdP/dtmax was observed in 12 of 15 patients (80%), who were classiﬁed as respon-
ders to CRT. In nine of 12 responders (75%), the optimal pacing conﬁguration identiﬁed by the PEAarea
method was associated with the greatest LV dP/dtmax.
Conclusion The concordance of the PEAarea method with measurements of LVdP/dtmax suggests that this
new, operator-independent algorithm is a reliable means of CRT optimization.
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Introduction
Cardiac resynchronization therapy (CRT) is an established
therapy for patients with advanced, congestive heart
failure (CHF) associated with cardiac dyssynchrony. The
mechanisms of action of CRT are complex, as it interacts
with several electromechanical variables, including atrio-
ventricular (AV), interventricular (VV), intraventricular,
and intramural delays. Information regarding the optimal
programming and follow-up of these devices are limited.
Left ventricular (LV) dP/dtmax and several non-invasive
indices have been used to optimize the functions of CRT
devices, in particular AV delay (AVD) and VV conﬁguration,
1–6
and recent clinical experience has conﬁrmed the need for,
and beneﬁts of their long-term reprogramming, as their
optimal stimulation settings might change over time.
7–10
A direct assessment of changes in systolic function (LVdP/
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As a consequence, in clinical practice, the optimization of
CRT is usually achieved with the assistance of non-invasive
echocardiographic procedures, which can only be performed
with the patient supine, and are costly, time-consuming,
and operator-dependent.
A haemodynamic sensor integrated in a CRT pulse genera-
tor, which automatically calculates and optimizes the pro-
grammable settings of the device, might be an objective
means of assessing and adjusting therapy, also during activi-
ties or exercise.
As the myocardium contracts isometrically, it generates
muscular and valve vibrations (endocardial accelerations)
that are transmitted throughout the heart and thus
measured with an implantable microaccelerometer located
inside the tip of a conventional unipolar pacing lead.
These vibrations, in their audible component, are respon-
sible for the ﬁrst heart sound. A pacing system equipped
with a microaccelerometer sensor (PEA sensor), able to
measure the peak of the endocardial acceleration during
the isovolumic contraction phase (ﬁrst component of the
signal here deﬁned as ‘PEA’), has been previously developed
and clinically evaluated.
11,12 The system allows monitoring
of myocardial function by means of PEA, which was ident-
iﬁed as an expression of cardiac contractility.
13 Till now,
several clinical applications and tools based on PEA assess-
ment have been proposed.
14–17
A new CRT-P device (The New LivingTM CHF, Sorin Group
CRM, Saluggia, Italy) equipped with an implantable PEA
sensor has been recently developed to monitor cardiac
function and guide CRT programming in patients affected
by CHF.
This study examined the performance of a new CRT
optimization algorithm based on PEA measurements
(PEAarea method) in the identiﬁcation of the optimal CRT
pacing conﬁguration, compared with direct measurements
of LV pressure (LVdP/dtmax).
Methods
Patient population
The study included 15 patients (mean age ¼ 72+8 years, 13
men) with indications of CRT in accordance with standard
international guidance. They were in New York Heart Associ-
ation (NYHA) CHF functional class II–IV, despite stable
optimal medical therapy, including b-adrenergic blockers
(n ¼ 14) and angiotensin-converting enzyme-inhibitors or
angiotensin II blockers (n ¼ 13). All patients were in sinus
rhythm. Their mean echocardiographic LV ejection fraction
(EF) was  35% (mean ¼ 23+8%) and QRS duration
.130 ms (mean ¼ 170+16 ms). The underlying heart
disease was ischaemic in eight and non-ischaemic in seven
patients. Exclusion criteria were: possible surgical treat-
ment (myocardial revascularization or valve replacement),
life-threatening ventricular arrhythmias, right ventricular
(RV) dimension superior to LV dimension, myocardial infarc-
tion, coronary artery bypass grafting (CABG) within last 3
months, patient already implanted with a conventional
pacemaker. The study protocol was approved by our insti-
tutional review committee, and all patients granted their
informed consent before enrolment.
Implantation of the cardiac resynchronization
system
All patients underwent implantation of LivingTM CHF or
NewLivingTM CHF CRT pulse generators (Sorin Group CRM),
connected to standard atrial and LV pacing leads. The LV
lead was inserted transvenously through the coronary
sinus, preferably into a lateral or postero-lateral cardiac
vein. A pacing lead (BESTTM, Sorin Group CRM) with a micro-
accelerometer sensor inside its tip was implanted at the RV
apex to record the PEA signal. At implant, all pulse genera-
tors were programmed in dual chamber atrioventricular
synchronous (DDD) mode and simultaneous biventricular
(BiV) stimulation (VV ¼ 0), and the AVD was adjusted to
ensure full electrical pre-excitation of the ventricles
during DDD pacing. The average AVD was 154+20 ms.
Catheterization procedure
At a mean interval of 39+15 days after implantation of the
CRT system, the patients underwent cardiac catheterization
under mild sedation. Haemodynamic measurements were
performed using a 7F pigtail catheter equipped with a high-
ﬁdelity pressure transducer (CD-Leycom, Zoetermeer, The
Netherlands). The catheter was advanced into the LV from
the left femoral artery and connected to a signal-conditioning
module (Sentron, Roden, The Netherlands) to record pressure.
Stimulation protocol
After placement of the pressure catheter, the heart was
stimulated programming the device with a PMP 2000Texter-
nal programmer (Sorin Group CRM).
The protocol included single LVand BiV stimulation, either
simultaneously (BiV0), or sequentially at VV intervals of 12
or 40 ms, with LV (LR12, LR40) or RV (RL12, RL40) preactiva-
tion, in a random order. At each of these conﬁgurations,
the AVD was scanned between the shortest 60 ms and
the longest 220 ms interval, with four increments of
AVDstep calculated as (PR 2 90)/4 ms. The ﬁve tested AVD
intervals were: 60 ms, 60 þ 1   AVDstep ms, 60 þ 2   AVDstep
ms, 60 þ 3   AVDstep ms, and 60 þ 4   AVDstep ms. The AVD
scans performed for each patient are listed in Table 1.
Data sampling and analysis
PEA signals, LV pressure with LV dP/dtmax calculation,
and analog electrocardiographic signals were recorded
simultaneously, using a MP100 acquisition system (Biopac
System Inc., Goleta, CA, USA) at a sampling rate of
1000 Hz for each channel. For each pacing conﬁguration, a
10-s programming period was required and a 30-s recording
period was preceded by a stabilization period of 30 s (i.e.
a total of 70 s for each conﬁguration). According to the
stimulation protocol, six pacing conﬁgurations were tested
(RL40, RL12, BiV0, LR12, LR40, LV), performing AVD scanning
over ﬁve AVD intervals. Thus, the total time needed to ﬁnd
the optimal pacing conﬁguration with the new PEAarea
method was approximately 35 min (2100 s), calculated as
(70 s)   (6)   (5) ¼ 2100 s.
For PEA recordings, the voltage signal generated by the
acceleration was measured from peak to peak in gravity
(1 g ¼ 9.8 m/s
2). LV dP/dtmax and PEA were measured at
steady state, cycle-by-cycle, using the AcqKnowledge 3.8.1
analysis software (Biopac System Inc., Goleta, CA, USA),
P.P. Delnoy et al. 802and values, sampled over approximately 30 s, were
averaged. Cycles with failure to capture, affected by extra-
systolic events and post-extrasystolic cycles were excluded
from the analysis. LVdP/dtmax and PEA were ﬁrst measured
during intrinsic rhythm, used as the reference patient’s
status condition. The heart rate was kept constant by
atrial pacing for all subsequent stimulation sequences.
Optimization of cardiac resynchronization
Response to CRT was deﬁned as a  10% increase in LVdP/
dtmax, considered the gold standard to monitor cardiac func-
tion in clinical CRT studies,
9,10 as it is reliable, reproducible,
and not operator-dependent. For each patient, the optimal
CRTconﬁguration was determined by comparing the optimiz-
ation criteria based on measurements of LVdP/dtmax (LVdP/
dtmax method) vs. measurements of PEA (PEAarea method).
The new PEAarea method
Studies in animals have shown that the peak-to-peak value of
acceleration of heart vibrations (PEA), recorded during LV iso-
volumic contraction with an accelerometer sensor, corre-
sponds to the endocardial recording of the ﬁrst heart sound
(S1).
18 LV contractility, as expressed by the maximum rate of
rise of LV pressure (LV dP/dtmax), and the respective timing
of atrial and ventricular systoles (the AVD), are both major
and independent determinants of the amplitudes of S1 and
PEA, in normal and in failing hearts.
19–24 In normal hearts,
shortening of the AVD causes a rapid increase in PEA ampli-
tude, mainly determined by the degree of opening of the
mitral valve leaﬂets, strictly related to an increase in transmi-
tral ﬂow during the A wave, while LV dP/dtmax remains rela-
tively ﬁxed. Similar results have been shown in clinical
studies of CRT, where LV dP/dtmax remained nearly ﬁxed
with shortening of the AVD in case of successful resynchroniza-
tion procedures, whereas it decreased with shortening of
the AVD in case of unsuccessful resynchronization attempts.
10
The new PEAarea method is, according to these results,
based on measurements of the area under the PEA curve:
it is expected to have a lower PEAarea in case of unsuccessful
resynchronization attempts, because of LVdP/dtmax
decreasing for short AVDs, with respect to successful resyn-
chronization procedure in which LVdP/dtmax remained
nearly ﬁxed. For each tested VV interval setting, the area
of PEA curve was estimated, using a simpliﬁed formula, as
the average of PEA values measured during AVD scanning
(Figure 1A–D). Thus, the PEAarea is an index of both contrac-
tility variations and transmitral ﬂow variations, and we
assumed that an increase in the area reﬂects an increase
in overall haemodynamic beneﬁt achieved by the pro-
grammed conﬁguration.
Statistical analysis
The mean values of LVdP/dtmax, calculated over a period of
10 respiratory cycles at each pacing conﬁguration, were
compared, using the Student-Newman-Keuls test for com-
parison of multiple variables. This speciﬁc t-test for com-
parison of paired variables belonging to a group, takes into
account, for each paired comparison, the inﬂuence of all
variables included in the group. A value of at , 0.05 was
considered statistically signiﬁcant.
Results
Responder patients were identiﬁed by a  10% increase in LV
dP/dtmax. Among the 15 patients included in this study, 12
(80%) were responders, a proportion consistent with other
clinical studies of CRT.
9,10 In 9 out of the 12 responders
(75%), the results of the LVdP/dtmax and PEAarea methods
were concordant (Table 2). The haemodynamic responses
(LV dP/dtmax and PEAarea trends) for different pacing con-
ﬁgurations are shown in Figure 2A–D for the same four
representative patients used for showing the PEAarea curve
during AVD scanning in Figure 1A–D.
The overall means and standard deviations for LVdP/dtmax
and PEAarea values for pacing conﬁguration for each patient
were reported in Table 3.
Table 1 Scans of the atrioventricular delay
Patient no. Atrioventricular delay (ms)
60 80 90 100 110 120 140 150 160 180 220
1X X X X X X
2 X XXX X
3X X X X
4X X X X X
5X X X X X
6X X X X X X
7X X X X
8X X X X X
9X X X X X
10 X X X X X
11 X X X X X
12 X X X X X
13 X X X X X X
14 X X X X
15 X X X X X
Each scan was performed during single chamber left ventricular (LV) stimulation and during biventricular stimulation at 0, 12, and 40 ms VV intervals, with
LV (LR12, LR40) or right ventricular (RL12, RL40) preactivation.
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improvement with LV preactivation or single-chamber LV
stimulation in six, RV preactivation in three, and simul-
taneous biventricular stimulation in two responders. LV pre-
activation or single chamber LV stimulation was associated
with the greatest haemodynamic improvement by at least
one method in nine, RV preactivation in ﬁve, and BiV stimu-
lation in four responders. Finally, in eight responders, more
than one optimal stimulation conﬁguration (range 2–4) were
identiﬁed by the LVdP/dtmax method (including opposite
ventricular preactivation in two patients), whereas the
PEAarea method identiﬁed a single optimal conﬁguration in
all responders (Table 2).
For each patient, the values of LVdP/dtmax increase in %
for the optimal pacing mode, compared with PEAarea varia-
tions in % for the optimal pacing mode, were summarized
in a scatter diagram plot (Figure 3).
Discussion
With the currently available CRT pulse generators, the AVD
and the VV interval have become programmable, and their
optimization is generally recommended, as an appropriate
selection of VV interval might further optimize LV function,
at implant as well as during follow-up.
25–32 Therefore, a
direct comparison of a new method of CRT optimization,
based on PEA measurements, with LVdP/dtmax, the haemo-
dynamic gold standard, was of particular interest. LV dP/
dtmax has been used previously as an index of LV perform-
ance in CRT.
27–29 However, it is inﬂuenced by heart rate,
preload, LV synchronization, and degree of mitral regurgita-
tion. Furthermore, when applied to optimize CRT, it requires
an invasive procedure, and its value is limited to short-term
observations. On the contrary, the optimization of CRT
based on individual adjustments of heart rate, AVD, VV
interval, and mode of stimulation can be accomplished
non-invasively in the long term, with the assistance of
haemodynamic sensors integrated in the implanted devices.
The perspective of being able to re-adjust CRT, with an
Figure 1 (A–D) Representative examples among cardiac resynchro-
nization therapy responder patients of (peak endocardial accelera-
tion) PEAarea curve measured during atrioventricular delay scanning
for different pacing conﬁgurations [RL40: sequential biventricular
pacing with 40 ms of right ventricular (RV) preactivation; RL12:
sequential biventricular pacing with 12 ms of RV preactivation;
LR12: sequential biventricular pacing with 12 ms of left ventricular
(LV) preactivation; LR40: sequential biventricular pacing with 40 ms
of LV preactivation; BiV0: simultaneous biventricular pacing].
Table 2 Concordance of the optimal pacing conﬁguration
identiﬁed by the LVdP/dtmax vs. PEAarea methods
Patient no. Optimal conﬁguration Concordance
LV dP/dtmax PEAarea
1 LR40, LV LR40 þ
2 BiV0, RL40, RL12, LR12 BiV0 þ
3N R N R N R
4N R N R N R
5 LR12, BiV0, LV, LR40 LR12 þ
6N R N R N R
7 LV RL12 2
8 BiV0, LR12 BiV0 þ
9 RL12 RL12 þ
10 RL12 RL40 2
11 LV, RL12 LV þ
12 LR12, LR40 LR12 þ
13 LR40, LV LR40 þ
14 LR40 LR12 2
15 RL12, BiV0, LR12 RL12 þ
þ, concordant; 2, non-concordant; NR, non-responder.
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PEA, at rest and during lifetime exercise activity, is attractive
and preferable to the echocardiographic procedures that are
currently applied in clinical practice only at follow-up. More-
over, the echocardiographic method is not so sensitive and
might not be able to detect subtle changes in LV systolic func-
tion. Therefore, the consistent results obtained with the
PEAarea method, validated by the direct measurements of LV
dP/dtmax, strongly support the introduction of this new
operator-independent method of CRT optimization into clini-
cal practice and implantable devices.
Study limitations
The absence of an automated stimulation protocol and data
analysis system limited the number of AVD used to calculate
the area of PEA curve and VV intervals we were able to test.
However, we believe that for preliminary evaluation of the
new PEA-based method a ﬁve-step AVD scanning may be
enough to provide meaningful data to estimate area under
the PEA curve.
The number of patients included in the present study
was relatively small, even if the rate of CRT responders
was comparable with data reported in literature.
33
Furthermore, our method, based on the measurement of
PEA during scanning of the AVD, is not applicable to patients
presenting with atrial ﬁbrillation.
Among 12 responders, according to the LVdP/dtmax
measurement, three patients showed no concordant
results between LVdP/dtmax and PEAarea method indications.
For one patient, during the procedure, we encountered
some problems with the pressure catheter that required
its repositioning. Even if we used the same calibrating pro-
cedure, the obtained LV dP/dtmax trend could have been
altered because of LVP recordings assessed before and
after catheter repositioning.
For the other two patients, the optimal CRTconﬁguration
indicated by PEAarea method is ‘adjacent’ to the best con-
ﬁguration indicated by LVdP/dtmax. This means that the
optimal conﬁguration indicated by LVdP/dtmax corresponds
to the ‘second optimal’ conﬁguration indicated by PEAarea
slightly lower than the optimal PEAarea value. Small differ-
ences can be observed between the optimal and the
‘second optimal’ CRT conﬁgurations indicated by PEAarea;
consequently, for these two patients we can say that, even
if PEAarea and LV dP/dtmax methods does not provide
exactly the same CRT best mode, however it is clear that
both identiﬁed the same optimal range of CRTconﬁgurations
Figure 2 (A–D) Comparison between (peak endocardial acceleration) PEAarea method and LVdP/dtmax method in identifying the optimal
stimulation conﬁguration for the same representative responder patients reported in Figure 1. Measurements made during intrinsic
rhythm were used as baseline to calculate% variation of PEAarea and LVdP/dtmax indexes. Symbol # indicates absence of signiﬁcant difference
between the two or more cardiac resynchronization therapy conﬁgurations by Student-Newman-Keuls analysis.
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vation—LR12, LR40—for the other). Moreover, for sequential
BiV stimulation we performed a VV interval scanning with
only two increments of VV step (12 ms, 40 ms). Probably, a
more reﬁned VV interval scanning (e.g. four increments of
VV step, from 12 to 40 ms) would have helped in determining
the optimal conﬁguration for these two ‘no concordant’
patients, as for both LV dP/dtmax and PEAarea methods the
best pacing mode could correspond to a conﬁguration with
VV interval included in the range of 12–40 ms.
We are working towards implementing the CRT-P device as
an automated stimulation protocol and PEAarea calculations
during AVD scanning in order to provide a more practical
and systematic method to apply for a more large and
complete clinical study. With this automated PEAarea
algorithm implemented in the device, the time needed to
ﬁnd the optimal pacing conﬁguration can be reduced up to
10–15 min, minimizing the programming and the recording
periods.
Finally, the outcomes of CRT optimization based on the
PEAarea method might not be predicted over an intermediate
or long-term follow-up. Thus, the long-term performance of
the PEAarea index must be clinically validated.
In the next clinical study, we are planning to validate the
method; results obtained with the automated PEAarea
algorithm implemented in the device will be compared with
clinical non-invasive measurements of cardiac performance
and CRT outcome (e.g. the 6 min-walk test), at implant and
during periodic follow-up (three or six months after implant).
Conclusions
Recent clinical studies have shown that CRT might require
reprogramming during follow-up. The proposed method,
based on measurements of the area under the PEA curve
during scanning of the AVD with different CRTconﬁgurations,
might be the answer to the need of automatic CRT
optimization at implant and during follow-up. The attain-
ment of concordant results with invasive haemodynamic
Table 3 Means and standard deviation (SD) for LVdP/dtmax and
PEAarea values for each pacing conﬁguration, for each patient
Patient
no.
LV dP/dtmax (mmHg/s) PEAarea (g)
Conﬁguration Mean+SD Conﬁguration Mean+SD
1 RL40 680+33 RL40 0.68+0.09
RL12 695+25 RL12 0.68+0.09
BiV0 724+38 BiV0 0.68+0.08
LR12 711+22 LR12 0.73+0.09
2 LR40 777+ + + + +35 LR40 0.77+ + + + +0.07
LV 778+ + + + +59 LV 0.63+0.06
RL40 1429+ + + + +39 RL40 1.63+0.16
RL12 1434+ + + + +57 RL12 1.62+0.17
BiV0 1440+ + + + +37 BiV0 1.65+ + + + +0.16
LR12 1425+ + + + +38 LR12 1.45+0.17
LR40 1341+38 LR40 1.19+0.17
LV 1270+32 LV 0.84+0.10
3N R N R N R N R
4N R N R N R N R
5 RL40 1289+43 RL40 0.97+0.10
RL12 1272+64 RL12 0.80+0.10
BiV0 1301+ + + + +99 BiV0 0.96+0.05
LR12 1347+ + + + +57 LR12 1.01+ + + + +0.07
LR40 1301+ + + + +86 LR40 0.98+0.08
LV 1355+ + + + +102 LV 0.92+0.05
6N R N R N R N R
7 RL40 1269+22 RL40 1.24+0.13
RL12 1257+28 RL12 1.33+ + + + +0.12
BiV0 1233+33 BiV0 1.26+0.11
LR12 1216+27 LR12 1.23+0.12
LR40 1271+68 LR40 1.00+0.11
LV 1303+ + + + +61 LV 0.56+0.07
8 RL40 644+29 RL40 2.17+0.28
RL12 683+26 RL12 2.12+0.45
BiV0 704+ + + + +26 BiV0 2.21+ + + + +0.34
LR12 707+ + + + +20 LR12 2.12+0.27
LR40 678+19 LR40 2.14+0.33
LV 680+39 LV 1.94+0.22
9 RL40 1388+35 RL40 0.31+0.03
RL12 1509+ + + + +64 RL12 0.32+ + + + +0.02
BiV0 1292+59 BiV0 0.29+0.02
LR12 1221+42 LR12 0.29+0.01
LR40 1285+51 LR40 0.26+0.02
LV 1257+41 LV 0.30+0.02
10 RL40 1160+24 RL40 0.11+ + + + +0.01
RL12 1195+ + + + +38 RL12 0.10+0.01
BiV0 1137+26 BiV0 0.08+0.01
LR12 1161+28 LR12 0.08+0.01
LR40 1121+21 LR40 0.08+0.01
LV 1094+23 LV 0.09+0.01
11 RL40 825+21 RL40 0.51+0.08
RL12 845+ + + + +45 RL12 0.51+0.07
BiV0 479+21 BiV0 0.56+0.08
LR12 779+24 LR12 0.64+0.07
LR40 815+22 LR40 0.73+0.06
LV 840+ + + + +27 LV 0.74+ + + + +0.07
12 RL40 888+22 RL40 0.65+0.08
RL12 903+50 RL12 0.71+0.11
BiV0 1004+31 BiV0 0.83+0.07
LR12 1038+ + + + +76 LR12 0.86+ + + + +0.14
LR40 1059+ + + + +51 LR40 0.75+0.05
LV 998+36 LV 0.59+0.06
13 RL40 1271+46 RL40 0.45+0.03
RL12 1259+36 RL12 0.38+0.03
Continued
Table 3 Continued
Patient
no.
LV dP/dtmax (mmHg/s) PEAarea (g)
Conﬁguration Mean+SD Conﬁguration Mean+SD
BiV0 1265+30 BiV0 0.39+0.03
LR12 1298+31 LR12 0.43+0.04
LR40 1332+ + + + +53 LR40 0.47+ + + + +0.02
LV 1341+ + + + +58 LV 0.46+0.03
14 RL40 901+21 RL40 0.55+0.05
RL12 910+30 RL12 0.61+0.08
BiV0 954+20 BiV0 0.66+0.07
LR12 944+28 LR12 0.67+ + + + +0.06
LR40 989+ + + + +20 LR40 0.66+0.05
LV 964+20 LV 0.43+0.05
15 RL40 1140+31 RL40 1.20+0.17
RL12 1367+ + + + +49 RL12 1.24+ + + + +0.11
BiV0 1389+ + + + +44 BiV0 1.13+0.12
LR12 1358+52 LR12 1.04+0.11
LR40 1249+56 LR40 1.05+0.11
LV 1210+113 LV 0.76+0.11
Bold denotes optimal pacing conﬁguration.
P.P. Delnoy et al. 806measurements in the majority of responders warrant further
testing of this operator-independent and expeditious
method of CRT optimization in a larger patient population.
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